Advertisement

Fall 59: Spätschäden – 51 Jahre, ♂, DM Typ 2, Herzinfarkt- und Schlaganfallrisiko

  • Stefan Kopf
Chapter

Zusammenfassung

Ein 51-jähriger Typ-2-Diabetiker, ohne koronare Herzerkrankung, einem normalen Blutdruck, einem HbA1c von 8,1 und einem LDL von 163 mg/dl kommt voller Sorge, da er alle Statine nicht verträgt, und möchte wissen, wie er sein Risiko eines Herzinfarktes und wie das eines Schlaganfalles weiter senken kann. Welche Therapien machen Sinn?

Literatur

  1. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559.  https://doi.org/10.1056/nejmoa0802743
  2. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560–2572.  https://doi.org/10.1056/nejmoa0802987
  3. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Investigators I-I (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 372(25):2387–2397.  https://doi.org/10.1056/NEJMoa1410489CrossRefPubMedGoogle Scholar
  4. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Monique Verschuren WM, Vlachopoulos C, Wood DA, Luis Zamorano J, Additional C, Cooney MT (2017) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Rev Esp Cardiol (Engl Ed) 70(2):115.  https://doi.org/10.1016/j.rec.2017.01.002CrossRefGoogle Scholar
  5. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, Investigators V (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129–139.  https://doi.org/10.1056/NEJMoa0808431CrossRefPubMedPubMedCentralGoogle Scholar
  6. Harvey PD, Sabbagh MN, Harrison JE, Ginsberg HN, Chapman MJ, Manvelian G, Moryusef A, Mandel J, Farnier M (2018) No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J 39(5):374–381.  https://doi.org/10.1093/eurheartj/ehx661CrossRefPubMedGoogle Scholar
  7. Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, Miedema MD, Khalili H, Ahmad Z, Abdullah S, Banerjee S, Brilakis ES (2017) Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials. J Am Heart Assoc 6 (12).  https://doi.org/10.1161/jaha.117.006910
  8. Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Ghazarian S, Gregg EW, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricio J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369(2):145–154.  https://doi.org/10.1056/NEJMoa1212914CrossRefGoogle Scholar
  9. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N (2010) Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 170(12):1024–1031.  https://doi.org/10.1001/archinternmed.2010.182CrossRefGoogle Scholar
  10. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC, Investigators SCO (2017) Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. N Engl J Med 376(16):1527–1539.  https://doi.org/10.1056/NEJMoa1701488CrossRefPubMedGoogle Scholar
  11. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, Committee FS, Investigators (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 376(18):1713–1722.  https://doi.org/10.1056/NEJMoa1615664CrossRefPubMedGoogle Scholar
  12. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Abteilung Innere Medizin IMedizinische UniversitätsklinikHeidelbergDeutschland

Personalised recommendations